Also, the low hazard ratios for prescriptions of P2Y12 inhibitors, aspirin, and statins may be more profound than the expected benefits, with results arising in part from selection by physicians for those who receive prescriptions based on underlying conditions other than coronary disease. The gene discussed is P2RY12; the disease is coronary artery disorder.